Theravance Biopharma, Inc. (TBPH)

Every figure this model derived for TBPH, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 42,000 PaymentsToAcquireProductiveAssets 2025-12-31
cash 387,657,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 416,662,000 AssetsCurrent 2026-06-30
current liabilities 30,766,000 LiabilitiesCurrent 2026-06-30
equity 289,705,000 StockholdersEquity 2026-06-30
interest expense 2,461,000 InterestExpenseNonoperating 2025-12-31
ocf 53,742,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 104,311,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 19,550,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TBPH on one particular measure came for.

RatioValue
cash operating margin16.15
current ratio13.54
current ratio reported13.54
deferred revenue growth0.0
dilution pct5.45
fcf margin51.48
growth cv2.5
interest cover-1.71
operating margin-4.03
owner earnings margin32.74
revenue growth35.11
revenue growth per share28.13
rule of 4031.08
sbc pct revenue18.74

What to be careful about

What this model itself distrusts about TBPH's figures. Written by the derivation as it ran, not added afterwards.